Literature DB >> 23303914

Relaxin family peptides and their receptors.

R A D Bathgate1, M L Halls, E T van der Westhuizen, G E Callander, M Kocan, R J Summers.   

Abstract

There are seven relaxin family peptides that are all structurally related to insulin. Relaxin has many roles in female and male reproduction, as a neuropeptide in the central nervous system, as a vasodilator and cardiac stimulant in the cardiovascular system, and as an antifibrotic agent. Insulin-like peptide-3 (INSL3) has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. Although they are structurally related to insulin, the relaxin family peptides produce their physiological effects by activating a group of four G protein-coupled receptors (GPCRs), relaxin family peptide receptors 1-4 (RXFP1-4). Relaxin and INSL3 are the cognate ligands for RXFP1 and RXFP2, respectively, that are leucine-rich repeat containing GPCRs. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Relaxin-3 and INSL5 are the cognate ligands for RXFP3 and RXFP4 that are closely related to small peptide receptors that when activated inhibit cAMP production and activate MAP kinases. Although there are still many unanswered questions regarding the mode of action of relaxin family peptides, it is clear that they have important physiological roles that could be exploited for therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303914     DOI: 10.1152/physrev.00001.2012

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  153 in total

1.  Relaxin increases sympathetic nerve activity and activates spinally projecting neurons in the paraventricular nucleus of nonpregnant, but not pregnant, rats.

Authors:  K Max Coldren; Randall Brown; Eileen M Hasser; Cheryl M Heesch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-23       Impact factor: 3.619

2.  Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3.

Authors:  Martina Kocan; Sheng Yu Ang; Roger J Summers
Journal:  Neurochem Res       Date:  2015-08-21       Impact factor: 3.996

3.  Relaxin as a hormonal aid to evaluate pregnancy and pregnancy loss in bottlenose dolphins (Tursiops truncatus).

Authors:  Don R Bergfelt; Jason L Blum; Bernard G Steinetz; Karen J Steinman; Justin K O'Brien; Todd R Robeck
Journal:  Gen Comp Endocrinol       Date:  2015-12-24       Impact factor: 2.822

4.  Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction.

Authors:  Jesus Sanchez-Mas; Antonio Lax; Mari C Asensio-Lopez; Miriam Lencina; Maria J Fernandez-Del Palacio; Angela Soriano-Filiu; Rudolf A de Boer; Domingo A Pascual-Figal
Journal:  J Cardiovasc Transl Res       Date:  2017-07-17       Impact factor: 4.132

Review 5.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 6.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

7.  Structure-function analyses of a pertussis-like toxin from pathogenic Escherichia coli reveal a distinct mechanism of inhibition of trimeric G-proteins.

Authors:  Dene R Littler; Sheng Y Ang; Danilo G Moriel; Martina Kocan; Oded Kleifeld; Matthew D Johnson; Mai T Tran; Adrienne W Paton; James C Paton; Roger J Summers; Mark A Schembri; Jamie Rossjohn; Travis Beddoe
Journal:  J Biol Chem       Date:  2017-06-29       Impact factor: 5.157

8.  Relaxin-2 therapy reverses radiation-induced fibrosis and restores bladder function in mice.

Authors:  Youko Ikeda; Irina V Zabbarova; Lori A Birder; Peter Wipf; Samuel E Getchell; Pradeep Tyagi; Christopher H Fry; Marcus J Drake; Anthony J Kanai
Journal:  Neurourol Urodyn       Date:  2018-05-28       Impact factor: 2.696

9.  Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Authors:  Helen E Burston; Oliver A Kent; Laudine Communal; Molly L Udaskin; Ren X Sun; Kevin R Brown; Euihye Jung; Kyle E Francis; Jose La Rose; Joshua Lowitz; Ronny Drapkin; Anne-Marie Mes-Masson; Robert Rottapel
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 10.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.